

American Academy of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

[Disclosure of Commercial Support for AAP CME Activities](#)

The AAP gratefully acknowledges support for the 2026 National Conference & Exhibition. The full list of supporters can be found here: <https://aapexperience.org/education-supporters/>

[Disclosure of Financial Relationships and Mitigation of Conflicts of Interest for AAP CME Activities Grid](#)

The AAP recognizes that there are a variety of financial relationships between individuals and ineligible companies that require review to identify possible conflicts of interest in a CME activity. The "AAP Policy on Disclosure of Financial Relationships and Mitigation of Conflicts of Interest for AAP CME Activities" is designed to ensure quality, objective, balanced, and scientifically rigorous AAP CME activities by identifying and mitigating all potential conflicts of interest prior to the confirmation of service of those in a position to influence and/or control CME content. AAP has taken steps to mitigate any potential conflicts of interest. The purpose of this policy is to ensure all potential conflicts of interest are identified and mechanisms to mitigate them prior to the CME activity are implemented in ways that are consistent with the public good. The AAP is committed to providing learners with commercially unbiased CME activities.

All AAP CME activities will strictly adhere to the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. In accordance with these Standards, the following decisions will be made free of the control of an ineligible company: identification of CME needs, determination of educational objectives, selection and presentation of content, selection of all persons and organizations that will be in a position to control the content, selection of educational methods, and evaluation of the CME activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Name of Ineligible Company*
		Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Allen, Kiona	Faculty	Mezzion: Research Grant
Amdani, Shahnawaz	Faculty	Mezzion: Research Grant
Anderson, William	Faculty	StethX: Consultant ALK; Sanofi; Teva: Advisory Board Member
Anderson, Sarah Ann	Abstract Reviewer	Afaxys: Consultant
Ardura, Monica	Faculty	MiraVista Diagnostics: Research Grant
Aronson, Paul	Abstract Reviewer	Merck: Research Grant
Badaki-Makun, Oluwakemi	Faculty	Beckman Coulter: Research Grant
Badaki-Makun, Kemi	Abstract Reviewer	Beckman Coulter: Research Grant
Baker-Smith, Carissa	Faculty	Merck Pharmaceuticals: Advisory Board Member
Belsky, Jennifer	Abstract Reviewer	Bristol Meyers Squibb: Consultant
Bent, Melissa	Faculty	Cast21: Principal Investigator
Bhatia, Rajeev	Planning Group Committee	Merck Manual: Consultant
Bhattacharjee, Rakesh	Faculty	Avadel Pharmaceuticals; Jazz Pharmaceuticals: Consultant Harmony Biosciences: Speaker Bureau

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Bird, John	Moderator	Allakos; DBV Technologies; Genentech; Hanimmune Theraeutics; Parexel: Consultant Infant Health; ALK Abello; DBV Technologies; Genentech; Novartis; Siolta: Independent Contractor
Blitz, Robin	Abstract Reviewer, Faculty	UnitedHealthcare: Employee/Owner
Boull, Christina	Faculty	SpringWorks Therapeutics: Consultant, Sonni, Inc: Advisory Board Member
Braham, Sabrina	Faculty	Wellio.Health: Employee/Owner
Bruggeman, Brittany	Faculty	GentiBio; MannKind Corporation: Research Grant
Butte, Manish	Faculty	ADMA: Advisory Board Member X4; Pharming: Research Grant
Byrne, Bobbi	Teaching Assistant	Fisher & Paykel Healthcare: Consultant
Campbell, James	Faculty	Sanofi; GSK; Moderna; Merck; Pfizer: Research Grant
Carvalho, Daniela	Teaching Assistant	Regeneron: Principal Investigator, Advisory Board Member
Chaffee, Tonya	Planning Group/Committee	Hologic: Consultant, Organon: Trainer
Champaigne, Neena	Faculty	Stealth Biotherapeutics: Consultant, Denali Therapeutics: Speaker Bureau
Chan, Sherwin	Faculty	Jazz Pharmaceuticals: Research Grant, GE Healthcare: Consultant
Chang, Johanna	Faculty	Novartis: Principal Investigator
Chatfield, Kathryn	Faculty	Stealth Biotherapeutics: Consultant
Chung, Richard	Abstract Reviewer, Planning Group/Committee	Pfizer: Consultant
Collins, Allison	Faculty	Vydiant: Consultant
Coleman, Nailah	Abstract Reviewer	GoodSport, Inc: Advisory Board Member
Connolly, Sean	Abstract Reviewer	GlaxoSmithKline: Consultant
Corkins, Mark	Faculty	American Reagent; Takeda Pharmaceuticals, USA: Principal Investigator
Craig, Clifford	Abstract Reviewer	Johnson and Johnson: Stockholder
Cruz, Andrea	Faculty	Pfizer: Research Grant
Cuda, Suzanne	Faculty	Lilly Pharmaceuticals: Speaker Bureau
Curtin, Michelle	Faculty	GeneDx: Advisory Board Member
Cymbaluk, Anna	Faculty	MannKind Corporation: Advisory Board Member, Speaker Bureau Tandem Diabetes Care: Advisory Board Member, Consultant
Daphtary, Kshama	Abstract Reviewer	Gilead; Merck; Roche Holdings: Stockholder
Darbari, Anil	Abstract Reviewer	Abbott Nutritionals: Speaker Bureau
Darden, Paul	Abstract Reviewer	GSK: Research Grant
Davis, Carla	Faculty	Novartis: Research Grant
del Moral, Teresa	Faculty	Mead Johnson: Advisory Board Member
Deville, Jaime	Teaching Assistant	Gilead Sciences; Pfizer; Entasis: Research Grant
Diasio, Christoph	Abstract Reviewer	Pfizer: Sub-Principal Investigator
DiVall, Sara	Faculty	Serono Therapeutics: Research Grant
Dumitrescu, Alina	Moderator	reVision Therapeutics, Inc: Advisory Board Member Janssen Pharmaceuticals, Inc: Consultant Mitsubishi Tanabe Pharma America, Inc: Consultant Digital Diagnostics Inc: Stockholder
Ebersole, Ashley	Abstract Reviewer	BioMérieux: Research Grant
Ekhuagere, Osayame	Abstract Reviewer	LoMIC Health Technology: Employee/Owner
Emerson, Beth	Abstract Reviewer	Biohaven Pharmaceuticals: Employee
Enyedi, Laura	Faculty	Fera Pharmaceuticals: Consultant
Fiscus, Michelle	Abstract Reviewer	Merck: Advisory Group Member
Fisher-Owens, Susan	Faculty, Teaching Assistant	Colgate: Consultant
Flyer, Jonathan	Abstract Reviewer	Regeneron: Advisory Board Member
Fox, Jenny Rose	Teaching Assistant	Prolacta: Speaker Bureau

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Gardiner, Michael	Moderator	Knoa Pharma: Consultant
Gardiner, Mike	Abstract Reviewer	Purdue Pharma: Consultant
Gershanik, Esteban	Abstract Reviewer	Johnson and Johnson; Amgen; Eli Lilly Co; Pfizer: Stockholder Tendo: Advisory Board Member UzObi, Inc: Consultant
Gewirtz O'Brien, Janna	Plenary Faculty	Organon: Speaker Bureau
Goday, Praveen	Faculty	Kate Farms/Nutricia: Research Grant Abbott: Consultant
Goldstein, Rachel	Abstract Reviewer, Faculty	Organon: Trainer
Graham, Robert	Faculty	Astellas Pharmaceuticals: Consultant
Groves, Alan	Faculty	GE Healthcare: Consultant
Gupta, Ruchi	AAP Section/Council Program Chair, Moderator	Genentech; DBV Technologies; Novartis; OWYN; Kaleo; Bryn Pharma; ARS Pharmaceuticals: Consultant Abbott Laboratories; Genentech; Novartis: Research Grant Yobee Care, Inc. Ownership Interest
Gupta, Deepti	Faculty	Nexus Outreach: Research Grant Noble Pharma: Royalties Pierre Fabre: Compensation
Gupta, Sandeep	Faculty	Aardvark; AstraZeneca; Ello: Consultant/DSMB Member
Gupta, Meera	Faculty	Sanofi-Genzyme; Regeneron; Astra-Zeneca: Advisory Board Member Teva Pharmaceuticals; Regeneron; Sanofi-Genzyme: Principal Investigator
Gupta, Payel	Faculty	Sanofi; Regeneron; AstraZeneca; Novartis; Blueprint: Advisory Board Member
Hackell, Jesse	Abstract Reviewer, Faculty	Sanofi; Sanofi USA; Seqirus USA: Advisory Board Member
Hamling, Alex	Abstract Reviewer	Merck: Consultant
Han, Joan	Faculty	Rhythm Pharmaceuticals: Principal Investigator
Handel, Andrew	Abstract Reviewer	GSK: Honorarium
Hannon, Tamara	Faculty	Eli Lilly, Inc; Novo Nordisk: Research Grant
Harpavat, Sanjiv	Abstract Reviewer	Syneos Health: Member
Harris, Christopher	Abstract Reviewer/Moderator	Enanta Pharmaceuticals: Employee/Owner
Hassan, Sara	Faculty	IPSEN: Consultant
Henson, Sarah	Faculty	AstraZeneca Pharmaceuticals LP: Consultant
Henstenburg, Jeff	Faculty, Moderator	Medtronic: Consultant
Hogan, Angela	AAP Section/Council Program Chair, Faculty, Moderator	ARS: Speaker Bureau
Hubbard, Dena	Abstract Reviewer, Teaching Assistant	Abbott Nutrition: Speaker Bureau
Hudson, Jeff	Staff	CVS: Stockholder
Hunter, Brandon	Faculty	DM1 LLC; ; KidTech: Advisory Board Member Neotech Products: Consultant
Ignacio, Romeo	Abstract Reviewer, Faculty	Critical Innovations: Consultant AbbVie; Abbott Laboratories: Stockholder
Jacobson, Robert	Abstract Reviewer	3M Company; Abbott laboratories: AbbVie Company; Adobe Inc., Baxter; Becton Dickinson & Co; Eli Lilly & Company; Embecta; Hubbell, Inc; Johnson & Johnson; Medtronic PLC F; Schwab S & P 500; Solvatum Corp; Takeda Pharma Co.; Zimmer Biomet Holdings; Zimvie Inc.; Merck & Co., Inc. Honorarium
James, Alexandra	Faculty	Linus Bio: Consultant
Jatana, Kris	Faculty	Zotarix LLC; Landsdowne Labs LLC; Tivic Health Systems: Stockholder, Marpac Inc; Grace Medical: Royalties
Joseph, Francesca	AAP Section/Council Program Chair, Moderator	Trigg Health: Co-Founder
Kan, Kristin	Faculty	Kaleo; ARS Pharma: Consultant

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Kapadia, Vishal	Teaching Assistant	Anishe, Inc: Founder Masimo Corporation: Research Grant
Kaul, Paritosh	Planning Group/Committee	Syneoshealth: Consultant
Kelsey, Megan	Faculty	Medtronic: Speaker Rhythm Pharmaceuticals: Principal Investigator
Kim, Jae	Faculty	Mothers Milk is Best; Cardinal Health; Carag; Biomilq; Infant Biotherapeutics: Consultant Medela: Advisory Board Member Astarte Medical; Nicolette: Stockholder, Cardinal Health: Speaker Bureau Fresenius Kabi: Research Grant
Kim, Taylor	Faculty	Sobi: Consultant
Klein, Bruce	Faculty	Jonhson & Johnson: Stockholder
Kon, Alexander	Faculty	Ethics Consultants, Inc: Employee/Owner, ROMTech Inc: Stockholder
Lam, Sandi	Faculty	Ovid Therapeutics; Encoded Therapeutics; Jaguar Therapeutics: Consultant Synergia: Advisor LivaNova: Research Grant & Advisory Board Member
Lang, Pamela	Abstract Reviewer	Stryker Corporation: meal, Enduro Med LLC: training session
Law, Yuk	Faculty	Merck: Principal Investigator
Leone, David	Abstract Reviewer	TPRV Pharmaceuticals: Consultant
Lio, Peter	Faculty	Verdant Scientific; Bristol-Myers Squibb; Codex Labs; Concerto Biosciences; Hyphens Pharma; L'Oreal; Soteri Skin; Stratum Biosci; Thimble Health; Yobee Care; Almirall; Alphyn Biologics; Amyris: Advisory Board Member Eli Lilly; Arcutis; Galderma; Incyte; Pfizer; Pierre-Fabre Dermatologic; Sanofi; Verrica; AbbVie: Speaker Bureau Theraplex: Consultant
Liu, Raymond	Abstract Reviewer	Orthopediatrics: Royalties
Lobaugh, Lauren	Abstract Reviewer	Omniceil: Consultant
Logterman, Stephanie	Abstract Reviewer, Faculty, Moderator, Teaching Assistant	Arthrex, Inc: Consultant
Lohr, Jamie	Abstract Reviewer	Agitated Solutions, Inc; Abbott Medical: Consultant
Lou, Lily	Abstract Reviewer	Alcresta Therapeutics: Compensation
Loy, Michelle	AAP Section/Council Program Chair, Moderator, Teaching Assistant	Zarbees/Kenvue: Scientific Advisory Board
Mardjetko, Steven	Abstract Reviewer	SpineCraft Corporation: Advisory Board Member
Massey, Shavonne	Faculty	NeuroBell: Compensation, Sun Pharmaceuticals Ltd: Consultant
Mastrandrea, Lucy	AAP Section/Council Program Chair	Rhythm Pharmaceuticals; Spruce Biosciences; Lilly; Dompe Farmaceutici; Novo Nordisk: Principal Investigator
Merchant, Nadia	Faculty	Alexion; Kyowa Kirin; Pfizer; BridgeBio; BioMarin; Catalyst: Advisory Board Member
Metz, James	Teaching Assistant	Vertex Pharmaceuticals: Stockholder
Miyake, Christina	Faculty	Boston Scientific: Consultant
Modi, Biren	AAP Section/Council Program Chair, Abstract Reviewer, Faculty	Vertex Pharmaceuticals: Stockholder
Montez, Kimberly	Faculty	Boston Scientific; Regeneron Pharmaceuticals: Stockholder
Moore, Lindsey	Planning Group/Committee	AiMMUNE: Speaker Kenota Health: Principal Investigator Evidera: Consultant Genentech: Speaker Bureau Advisory Board Member

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Morse, Keith	Faculty	Baxter Healthcare: Advisory Board Member Janssen Pharmaceutical: Research Grant
Mudd, Pamela	Teaching Assistant	Precigen: Consultant
Muthurangu, Vivek	Faculty	Siemens: Research Grant
Nelson, Christina	Abstract Reviewer	Radnet Inc.: Stockholder
Neugut, Yael	Abstract Reviewer	Pfizer: Research Grant
Newland, Jason	Faculty	Pfizer; Moderna; Thermo Fisher; Principal Investigator Merck: Co-Investigator
Newman, Ross	Faculty	MiraFAST; IPG DEXTRA; BIOSECTOR 2 LLC: Compensation
Nguyen-Tran, Hai	Faculty	bioMérieux: Speaker Bureau
Nigrovic, Lise	Abstract Reviewer	Pfizer: Research Grant
Nowak-Wegrzyn, Anna	Faculty	ALK; DBV Technologies Research Grant, Advisory Board Member Siolta Therapeutics: Research Grant Genentech: Advisory Board Member Siemens: Consultant Sanofi: Speaker Bureau
Nutman, Sarah	Abstract Reviewer	Johnson & Johnson: Stockholder
Orange, Jordan	Faculty	AnaptysisBio: Data Safety Monitoring Board ADMA biologics: Advisory Board Member
Pacicca, Donna	Abstract Reviewer	Medtronic; Zimmer Biomet: Stockholder
Pageler, Natalie	Faculty	Ensemble Health Partners: Strategic Advisor
Patel, Niraj	Faculty	Kedrion: Principal Investigator Takeda; ADMA; Grifols; X4 Pharma; Pharming: Speaker Bureau, Janssen: Data Safety Monitoring Board Amgen: Consultant
Patel, Pratik	Faculty	Eurofins Viracor LLC: Research Grant
Patterson, Mary	Faculty	BioMarin: Principal Investigator
Petrikina, Joshua	Abstract Reviewer	Abbott Nutrition: Speaker Bureau
Ramchandrar, Nanda	Abstract Reviewer, Faculty	Entasis; Pfizer: Sub Investigator
Raymond-Flesch, Marissa	Faculty	Equip Health: Speaker Bureau
Reed, Jennifer	Abstract Reviewer	CVS Caremark; Thermo Fisher Scientific; IQVIA; Eli Lilly; Becton Dickinson; United Health Group; Intuitive Surgical; Stryker; Danaher: Stockholder
Ren, Dennis	Faculty	Glass Health: Consultant
Rochat, Ryan	Faculty	Moderna; Merck: Research Grant
Rome, Ellen	Faculty	Organon: Advisory Board Member
Rossano, Joseph	Abstract Reviewer	Bristol Myers Squibb; AskBio; Astellas; Merck; Bayer: Consultant
Rubin, Zachary	Faculty	AstraZeneca; ARS Pharmaceuticals: Speaker Bureau Thermo Fisher: Compensation Neez21: Advisory Board Member
Sawyer, Taylor	Faculty	Verathon Inc: Advisory Board Member
Schwab, Joseph	Abstract Reviewer	Bristol-Myers Squibb; Johnson and Johnson: Stockholder
Schwend, Richard M	Abstract Reviewer	Orthopediatrics: Consultant
Sharma, Abhineet	Faculty	Ambu: Consultant
Short, Sonja	Abstract Reviewer	Pfizer: Consultant
Singh, Puja	Faculty	Sanofi: Independent Contractor, Educational Grant
Sirota, Susan	Planning Group/Committee	Pediametrix: Consultant
Slade, Renee	Faculty	Alcon Inc; UnitedHealth GP Inc; Proctor & Gamble; Nvidia Corporation; Abbott Laboratories; Novartis; CostCo; Dow Inc; General Mills Inc; Honeywell Intl Inc; Johnson & Johnson: Stockholder
Smith, Michael	Abstract Reviewer	Merck: Research Grant, Consultant Pfizer: Research Grant
Song, Clara	Abstract Reviewer, Faculty	Mead Johnson Nutrition: Speaker

DISCLOSURE OF FINANCIAL RELATIONSHIPS

All individuals in a position to influence and/or control the content of AAP CME activities are required to disclose to the AAP and subsequently to learners that the individual either has no financial relationships or any financial relationships with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in CME activities. An ineligible company is defined as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Listed below are the disclosures provided by individuals in a position to influence and/or control CME activity content. **All of the relevant financial relationships listed for these individuals have been mitigated.** This activity may discuss or demonstrate pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical.

All other faculty, planners and staff have reported no financial relationships with ineligible companies.

Name	Role	Name of Ineligible Company* Please list name(s) of entity AND Nature of Financial Relationship(s) (Please list: Research Grant, Speaker's Bureau, Stock/Bonds excluding mutual funds, Consultant, Other - identify)
Stafford, Diane	Faculty	Soleno Therapeutics: Advisory Board Member Acadia Pharmaceuticals; Ascendis Pharmaceuticals; Aardvark Therapeutics: Principal Investigator
Stewart, Paschal	Abstract Reviewer	PMG Research; Javara Research: Principal Investigator
Strominger, Mitchell	Moderator	Amgen: Speaker Bureau
Stukus, David	Faculty	ARS Pharmaceuticals; DBV Technologies: Principal Investigator, Genentech: Consultant
Swanson, Jonathan	Abstract Reviewer	Aerogen Pharma Limited; Gravitas: Research Grant Mednax, Inc; Prolacta Bioscience, Inc: Speaker Bureau
Sweeney, Brooke	Faculty	Rhythm: Research Grant, Principal Investigator, Consultant, Speaker Bureau Novo Nordisk; Eli Lilly; Nestle: Advisory Board Member
Tandon, Animesh	Abstract Reviewer	Synergen Health Technologies: Consultant
Tong, Carmen	Faculty	Novo Nordisk: Advisory Board Member
Travers, Colm	Abstract Reviewer	Owlet Baby Care Inc: Research Grant
Tully, Jeff	Faculty	Flexicare Inc: Consultant
Turek, Joseph	Abstract Reviewer	Surge Ingenuity Corp: Equity Stakeholder
Umoren, Rachel	Abstract Reviewer	Chiesi U.S.A.: Research Grant
Vidmar, Alaina P.	Faculty	Rhythm: Advisory Board Member
Walley, Susan	Abstract Reviewer	Atea Pharmaceuticals; Gilead Sciences, Inc.: Stockholder
Wang, George Sam	Faculty	Anebulo Pharmaceuticals: Consultant
Weakley, Kathryn	Faculty	Merck Sharp & Dohme LLC; GlaxoSmithKline; Pfizer: Sub-Investigator BioCryst Pharmaceuticals: Principal Investigator
Weems, Mark	Faculty	Abbott Congenital Heart: Speaker Bureau
Weinstein, Miriam	Faculty	Lilly: Advisory Board Member AbbVie: Speaker Bureau Incyte: Advisory Board Member, Speaker Bureau Sanofi: Sub-investigator La Roche Posay: Honorarium
Willis, Kent	Abstract Reviewer	Resbiotic Inc: Advisory Board Member
Wolynn, Todd	Faculty	Sanofi; Pfizer; Moderna; Merck: Consultant
Xanthakos, Stavra	Faculty	Novo Nordisk: Consultant
Yoo, Sylvia	AAP Section/Council Program Chair, Faculty, Moderator	Sydnexis: Principal Investigator
Waldron, Debra	Disclosure COI Reviewer & Mitigator	None
Hodge, Heather	Disclosure COI Reviewer & Mitigator	None